A Phase 1, Multi-Center, Placebo-Controlled, Dose-Escalation Study of the Safety of IMO-2125 in Hepatitis C-Infected Patients Unresponsive to Standard Treatment With Pegylated Interferon and Ribavirin

Trial Profile

A Phase 1, Multi-Center, Placebo-Controlled, Dose-Escalation Study of the Safety of IMO-2125 in Hepatitis C-Infected Patients Unresponsive to Standard Treatment With Pegylated Interferon and Ribavirin

Completed
Phase of Trial: Phase I

Latest Information Update: 15 May 2012

At a glance

  • Drugs IMO 2125 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Mar 2011 Status changed from active, no longer recruiting to completed based on information reported in an Idera Pharmaceuticals media release.
    • 01 Nov 2010 Status changed from recruiting to active, no longer recruiting.
    • 31 Oct 2010 Results have been presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), according to an Idera Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top